BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28598696)

  • 1. Pathology and molecular updates in tumors of the prostate: towards a personalized approach.
    Gasparrini S; Cimadamore A; Mazzucchelli R; Scarpelli M; Massari F; Raspollini MR; Galosi AB; Lopez-Beltran A; Cheng L; Montironi R
    Expert Rev Mol Diagn; 2017 Aug; 17(8):781-789. PubMed ID: 28598696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies.
    Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Epstein JI; Cascinu S; Briganti A; Catto JW; Montorsi F; Montironi R
    Eur Urol; 2016 Feb; 69(2):186-90. PubMed ID: 26070514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [TMPRSS2-Erg/AR-V7: Prognostic value of tests in urine and biopsy rince material in prostate cancer].
    Plante G; Bories PN; Denjean L; Pigat N; Sibony M; Goffin V; Barry Delongchamps N
    Prog Urol; 2020 Mar; 30(3):162-171. PubMed ID: 32127312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the presence of intraductal carcinoma of the prostate and bone metastasis in needle biopsy for prostate carcinoma patients with Grade Group 5.
    Chen X; Yang Y; Wang W; Han B; Qi M; Geng S; Xu J; Zhang Q; Wang X; Chen S; Shi K; Ke X; Zhang J
    Pathol Res Pract; 2020 Jan; 216(1):152693. PubMed ID: 31734052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
    Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
    Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
    Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal carcinoma of the prostate: What we know and what we do not know.
    Chen X; Ding B; Zhang P; Geng S; Xu J; Han B
    Pathol Res Pract; 2018 May; 214(5):612-618. PubMed ID: 29628124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer.
    Mertz KD; Horcic M; Hailemariam S; D'Antonio A; Dirnhofer S; Hartmann A; Agaimy A; Eppenberger-Castori S; Obermann E; Cathomas G; Bubendorf L
    Hum Pathol; 2013 Dec; 44(12):2727-35. PubMed ID: 24074533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
    Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
    J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists.
    Varma M; Egevad L; Algaba F; Berney D; Bubendorf L; Camparo P; Comperat E; Erbersdobler A; Griffiths D; Grobholz R; Haitel A; Hulsbergen-van de Kaa C; Langner C; Loftus B; Lopez-Beltran A; Mayer N; Nesi G; Oliveira P; Oxley J; Rioux-Leclercq N; Seitz G; Shanks J; Kristiansen G
    J Clin Pathol; 2016 Oct; 69(10):852-7. PubMed ID: 26926101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
    Gandhi JS; Smith SC; Paner GP; McKenney JK; Sekhri R; Osunkoya AO; Baras AS; DeMarzo AM; Cheville JC; Jimenez RE; Trpkov K; Colecchia M; Ro JY; Montironi R; Menon S; Hes O; Williamson SR; Hirsch MS; Netto GJ; Fine SW; Sirohi D; Kaushal S; Sangoi A; Robinson BD; Kweldam CF; Humphrey PA; Hansel DE; Schultz L; Magi-Galluzzi C; Przybycin CG; Shah RB; Mehra R; Kunju LP; Aron M; Kryvenko ON; Kench JG; Kuroda N; Tavora F; van der Kwast T; Grignon DJ; Epstein JI; Reuter VE; Amin MB
    Am J Surg Pathol; 2020 May; 44(5):673-680. PubMed ID: 31876580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
    Cohen RJ; Wheeler TM; Bonkhoff H; Rubin MA
    Arch Pathol Lab Med; 2007 Jul; 131(7):1103-9. PubMed ID: 17616999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.